scholarly journals Improvement in colorectal cancer outcomes over time is limited to patients with left-sided disease

2022 ◽  
Author(s):  
Holger Rumpold ◽  
M. Hackl ◽  
A. Petzer ◽  
D. Wolf
Keyword(s):  
Colorectal Cancer ◽  
Cancer Outcomes ◽  
Over Time

scholarly journals Improvement In Colorectal Cancer Outcomes Over Time is Limited To Patients With Left-Sided Disease

2021 ◽  
Author(s):  
Holger Rumpold ◽  
Monika Hackl ◽  
Andreas Petzer ◽  
Dominik Wolf
Keyword(s):  
Colorectal Cancer ◽  
Primary Tumor ◽  
Mortality Rates ◽  
Tumor Location ◽  
Mortality Data ◽  
Cancer Outcomes ◽  
Data Set ◽  
Primary Tumor Location ◽  
Incidence And Mortality ◽  
Over Time

Abstract Purpose: Incidence and mortality of colorectal cancer (CRC) declined over the last decades. However, survival depends on the primary tumor location. It is unknown if all progress in outcomes vary depending on left-sided (LCRC) versus right sided (RCC) colorectal cancer. We compare incidence and mortality rates over time according to the primary tumor location. Methods: Data from the Austrian National Cancer Registry spanning from 1983 to 2018 were used to calculate annual incidence and mortality rates and survival stratified by primary tumor localization and stage. Joinpoint regression with linear regression models were used on different subgroups to identify significant changes of incidence- and mortality slopes.Results: A total of 168,260 (incidence-data set) and 87,355 cases (mortality data-set) were identified. Survival of disseminated RCC was worse compared to LCRC (HR 1.14; CI 1.106 – 1.169). Total and LCRC incidence- and mortality-rates declined steadily over time, whereas the rates of RCC did not. Incidence of disseminated RCC declined significantly less (slope -0.07; CI -0.086; -0.055) than in LCRC (slope -0.159; CI -0.183; -0.136); mortality rate of RCC was unchanged over time. Incidence and mortality of localized RCC remained unchanged over time, whereas both rates declined independently of stage in LCRC. Conclusion: Colorectal cancer outcomes during the last 35 years have preferentially improved in LCRC but not in RCC, indicating that the progress made is limited to LCRC. It is necessary to define RCC as a distinct form of CRC and to focus on specific strategies for its early detection and treatment.

scholarly journals Associations between initiating antihypertensive regimens on stage I–III colorectal cancer outcomes: A Medicare SEER cohort analysis

2021 ◽  
Author(s):  
Rajesh Balkrishnan ◽  
Raj P. Desai ◽  
Aditya Narayan ◽  
Fabian T. Camacho ◽  
Lucas E. Flausino ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cohort Analysis ◽  
Stage I ◽  
Cancer Outcomes

Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy

2020 ◽  
Vol 17 (3) ◽  
pp. 185-194
Author(s):  
Jared Freml ◽  
Thomas Delate ◽  
Jesus Hermosillo-Rodriguez
Keyword(s):  
Colorectal Cancer ◽  
Retrospective Study ◽  
Cancer Therapy ◽  
Metastatic Colorectal Cancer ◽  
Small Proportion ◽  
Biomarker Testing ◽  
Over Time

Aim: To describe pharmacogenomic tumor testing among patients with metastatic colorectal cancer. Methods: This was a retrospective study of patients with metastatic colorectal cancer diagnosed between 1 January 2014 and 30 June 2018. Patients were assessed for pharmacogenomic testing and appropriateness of chemotherapy use. Results: Overall, 112/167 (67.1%) patients had at least one of the three recommended pharmacogenomic tests and 41/167 (24.6%) had all tests. Twenty-four patients were treated with cetuximab with 8/167 (4.7%) identified as being treated with a RAS variant (n = 3) or incomplete testing (n = 5); thus, not in accordance with guidelines. Conclusion: Uptake of testing was variable but increased over time; however, a small proportion of patients received cetuximab with a variant or not all recommended tests being performed.

Comparison of colorectal cancer outcomes in young adults and octogenarians

2021 ◽  
Author(s):  
Swetha Prabhakaran ◽  
Joseph Cherng Huei Kong ◽  
Evan Williams ◽  
Stephen Bell ◽  
Satish Warrier ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Young Adults ◽  
Cancer Outcomes

scholarly journals Diagnosis Setting and Colorectal Cancer Outcomes: The Impact of Cancer Diagnosis in the Emergency Department

2020 ◽  
Vol 255 ◽  
pp. 164-171
Author(s):  
David Weithorn ◽  
Vanessa Arientyl ◽  
Ian Solsky ◽  
Goyal Umadat ◽  
Rebecca Levine ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Emergency Department ◽  
Cancer Diagnosis ◽  
Cancer Outcomes ◽  
The Impact

scholarly journals Using cancer risk algorithms to improve risk estimates and referral decisions

2022 ◽  
Vol 2 (1) ◽  
Author(s):  
Olga Kostopoulou ◽  
Kavleen Arora ◽  
Bence Pálfi
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
Cancer Risk ◽  
General Practitioners ◽  
Learning Tools ◽  
Cancer Symptoms ◽  
Referral Decisions ◽  
Risk Estimates ◽  
Discernible Effect ◽  
Over Time

Abstract Background Cancer risk algorithms were introduced to clinical practice in the last decade, but they remain underused. We investigated whether General Practitioners (GPs) change their referral decisions in response to an unnamed algorithm, if decisions improve, and if changing decisions depends on having information about the algorithm and on whether GPs overestimated or underestimated risk. Methods 157 UK GPs were presented with 20 vignettes describing patients with possible colorectal cancer symptoms. GPs gave their risk estimates and inclination to refer. They then saw the risk score of an unnamed algorithm and could update their responses. Half of the sample was given information about the algorithm’s derivation, validation, and accuracy. At the end, we measured their algorithm disposition. We analysed the data using multilevel regressions with random intercepts by GP and vignette. Results We find that, after receiving the algorithm’s estimate, GPs’ inclination to refer changes 26% of the time and their decisions switch entirely 3% of the time. Decisions become more consistent with the NICE 3% referral threshold (OR 1.45 [1.27, 1.65], p < .001). The algorithm’s impact is greatest when GPs have underestimated risk. Information about the algorithm does not have a discernible effect on decisions but it results in a more positive GP disposition towards the algorithm. GPs’ risk estimates become better calibrated over time, i.e., move closer to the algorithm. Conclusions Cancer risk algorithms have the potential to improve cancer referral decisions. Their use as learning tools to improve risk estimates is promising and should be further investigated.

scholarly journals Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database

2021 ◽  
Author(s):  
George Kafatos ◽  
Victoria Banks ◽  
Peter Burdon ◽  
David Neasham ◽  
Caroline Anger ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Braf Mutation ◽  
European Countries ◽  
High Prevalence ◽  
Biomarker Testing ◽  
Colorectal Cancer Patients ◽  
Over Time

Background: The literature on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results: RAS testing was conducted in >90% of mCRC patients from 2014 onwards. BRAF testing increased from 31% of mCRC patients in 2013 to 67% in 2018. MSI testing increased from 10 to 41%. There was no notable trend over time for RAS and BRAF mutation or MSI-high prevalence. Conclusion: Biomarker testing among patients diagnosed with mCRC was increased over time. This study demonstrates the quick uptake of biomarker testing in clinical practice. These findings are significant as biomarker-based drugs are becoming more common.

scholarly journals Effect of Hospital Conditions on Short-Term Colorectal Cancer Outcomes: Experience of One Surgeon in Two Centers

2021 ◽  
Vol 31 (3) ◽  
pp. 210-216
Author(s):  
Ümit Alakuş ◽  
Süleyman Utku Çelik ◽  
Yaşar Subutay Peker ◽  
Barış Türker
Keyword(s):  
Colorectal Cancer ◽  
Cancer Outcomes ◽  
Short Term

Are we catching women in the safety net? Colorectal cancer outcomes by gender at a safety net hospital

2017 ◽  
Vol 214 (4) ◽  
pp. 715-720 ◽  
Author(s):  
Alison R. Althans ◽  
Justin T. Brady ◽  
Deborah S. Keller ◽  
Sharon L. Stein ◽  
Scott R. Steele ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Safety Net ◽  
Cancer Outcomes ◽  
Safety Net Hospital
Sign in / Sign up

Export Citation Format

Share Document